Embodiments of the disclosure include methods of increasing the efficacy of a fibroblast cell therapy for any medical condition, including degenerative disc disease, by providing at least one anti-inflammatory composition, exosomes and/or apoptotic bodies, stem cells, or a combination thereof; and administering the fibroblast cell therapy. The anti-inflammatory composition may comprise a composition that inhibits and/or reduces TNF-alpha, such as melatonin.

Embodiments of the disclosure include methods of increasing the efficacy of a fibroblast cell therapy for any medical condition, including degenerative disc disease, by providing at least one anti-inflammatory composition, exosomes and/or apoptotic bodies, stem cells, or a combination thereof; and administering the fibroblast cell therapy. The anti-inflammatory composition may comprise a composition that inhibits and/or reduces TNF-alpha, such as melatonin.

The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.

The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

The present invention relates to the pharmaceutically-induced enhancement of DNA damage repair in cells and potential therapeutic applications thereof. In particular, the present invention is directed to an inhibitor of DREAM complex assembly and/or function for use in repairing DNA damage in a cell of a subject. The inhibitor of DREAM complex assembly may be an inhibitory nucleic acid inhibiting the expression of a component of the DREAM complex or an antibody to a component of the DREAM complex. Further disclosed is an inhibitor of DREAM complex assembly and/or function for use in treating and/or preventing a condition associated with DNA damage in a cell in a subject, such as age-related diseases and symptoms of ageing, a progeroid syndrome, acute radiation syndrome, chronic radiation syndrome, Xeroderma pigmentosum, Nijmegen breakage syndrome, Fanconi anemia and ataxia. The invention further discloses a method for obtaining at least one cell with reduced DNA damage, wherein the method comprises steps of providing at least one cell, and treating said at least one cell with an inhibitor of DREAM complex assembly and/or function to repair DNA damage in said cell. Finally, the invention provides pharmaceutical compositions comprising the at least one cell obtainable by said method.

The present invention relates to the pharmaceutically-induced enhancement of DNA damage repair in cells and potential therapeutic applications thereof. In particular, the present invention is directed to an inhibitor of DREAM complex assembly and/or function for use in repairing DNA damage in a cell of a subject. The inhibitor of DREAM complex assembly may be an inhibitory nucleic acid inhibiting the expression of a component of the DREAM complex or an antibody to a component of the DREAM complex. Further disclosed is an inhibitor of DREAM complex assembly and/or function for use in treating and/or preventing a condition associated with DNA damage in a cell in a subject, such as age-related diseases and symptoms of ageing, a progeroid syndrome, acute radiation syndrome, chronic radiation syndrome, Xeroderma pigmentosum, Nijmegen breakage syndrome, Fanconi anemia and ataxia. The invention further discloses a method for obtaining at least one cell with reduced DNA damage, wherein the method comprises steps of providing at least one cell, and treating said at least one cell with an inhibitor of DREAM complex assembly and/or function to repair DNA damage in said cell. Finally, the invention provides pharmaceutical compositions comprising the at least one cell obtainable by said method.

The present disclosure relates to nanoparticles containing cellular membrane and uses thereof. The nanoparticle comprises an interior compartment (or an inner core) and an outer surface (or shell) comprising a cellular membrane derived from a cell, said interior compartment (or an inner core) not providing a solid support to said cellular membrane in said outer surface (or shell). The present disclosure also relates to processes of making the nanoparticles. The present disclosure further relates to compositions comprising the nanoparticles and methods of using the nanoparticles.